Efficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) study
Open Access
- 2 July 2007
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 8 (1) , 45
Abstract
Clinical trials of tiotropium have principally recruited patients from secondary care with more severe chronic obstructive pulmonary disease (COPD), and typically had included limitation of concomitant medication. In primary care, which is the most common setting for COPD management, many patients may have milder disease, and also may take a broad range of concomitant medication. This randomised, placebo-controlled, parallel-group, 12-week, 44-centre study investigated the efficacy (trough forced expiratory volume in 1 second [FEV1] response) and safety of additional treatment with once-daily tiotropium 18 μg via the HandiHaler® in a primary care COPD population (tiotropium: N = 191, FEV1 = 1.25 L [47.91% predicted]; placebo: N = 183, FEV1 = 1.32 L [49.86% predicted]). Secondary endpoints included: trough forced vital capacity (FVC) response, weekly use of rescue short-acting β-agonist, and exacerbation of COPD (complex of respiratory symptoms/events of >3 days in duration requiring a change in treatment). Treatment effects were determined using non-parametric analysis. At Week 12, median improvement in trough FEV1 response with tiotropium versus placebo was 0.06 L (p = 0.0102). The improvement was consistent across baseline treatment and COPD severity. Median improvement in FVC at 2, 6 and 12 weeks was 0.12 L (p < 0.001). The percentage of patients with ≥1 exacerbation was reduced (tiotropium 9.5%; placebo 17.9%; p = 0.0147), independent of disease severity. Rescue medication usage was significantly reduced in the tiotropium group compared with placebo. Adverse event profile was consistent with previous studies. Tiotropium provides additional benefits to usual primary care management in a representative COPD population. The identifier is: NCT00274079.Keywords
This publication has 30 references indexed in Scilit:
- Wirksamkeit von Tiotropiumbromid (Spiriva®) bei verschiedenen Schweregraden der chronisch-obstruktiven Lungenerkrankung (COPD)Pneumologie, 2006
- Questions for COPD diagnostic screening in a primary care settingRespiratory Medicine, 2005
- Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEuropean Respiratory Journal, 2005
- Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax, 2003
- Detection of asthma and chronic obstructive pulmonary disease in primary careEuropean Respiratory Journal, 2003
- A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEuropean Respiratory Journal, 2002
- Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task ForceEuropean Respiratory Journal, 1995
- Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways diseaseLife Sciences, 1995
- Role of the Parasympathetic System in Airway Obstruction Due to EmphysemaNew England Journal of Medicine, 1984
- Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease.BMJ, 1978